A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2009
11/26/2009	US20090291140 Treatment of dysmenorrhea via transdermal administration of nonsteroidal anti-inflammatory drugs
11/26/2009	US20090291139 Sparc and methods of use thereof
11/26/2009	US20090291138 Film-coated preparation having improved stability
11/26/2009	US20090291137 Solid oral form provided with a double release profile
11/26/2009	US20090291136 Multiple Unit Tablets
11/26/2009	US20090291135 Direct compression polymer tablet core
11/26/2009	US20090291134 Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
11/26/2009	US20090291133 Methods and compostions for enhancing transdermal drug delivery
11/26/2009	US20090291132 Enhanced delivery of antifungal agents
11/26/2009	US20090291131 Silencing of polo-like kinase expression using interfering rna
11/26/2009	US20090291130 Physiologically Active Polypeptide- or Protein-Encapsulating Polymer Micelles, and Method for Production of the Same
11/26/2009	US20090291129 Formulation of insoluble small molecule therapeutics in lipid-based carriers
11/26/2009	US20090291128 Transdermal delivery of cannabinoids
11/26/2009	US20090291127 Transdermal anti-dementia active agent formulations and methods for using the same
11/26/2009	US20090291126 Adhesive pharmaceutical preparation containing bisoprolol
11/26/2009	US20090291123 Opioid Combination Wafer
11/26/2009	US20090291122 Wound Care Treatment Product
11/26/2009	US20090291121 Capsule and coated capsules as a delivery system for dietary supplements and therapeutic materials
11/26/2009	US20090291120 Hydrophilic Polyurethane Compositions
11/26/2009	US20090291118 Universal barrier to prevent infections from human immunodeficiency virus
11/26/2009	US20090291117 Female barrier to prevent infections from human immunodeficiency virus
11/26/2009	US20090291115 Superporous hydrogel with cells encapsulated therein and method for producing the same
11/26/2009	US20090291111 Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
11/26/2009	US20090291108 Fabric with health care component
11/26/2009	US20090291106 Biodegradable block copolymers with modifiable surface
11/26/2009	US20090291105 Instant Vesicular Product
11/26/2009	US20090291104 Novel conotoxin framework with a helix-loop-helix fold
11/26/2009	US20090291098 Immunogenic LHRH compositions and methods relating thereto
11/26/2009	US20090291075 Binding agents and their use in targeting tumor cells
11/26/2009	US20090291050 Particulate materials
11/26/2009	US20090291049 Targeted delivery to human diseases and disorders
11/26/2009	US20090291020 Soft contact lens solution containing hyaluronic acid
11/26/2009	DE102008001788A1 Verwendung organomodifizierter Siloxanblockcopolymere zur Herstellung kosmetischer oder pharmazeutischer Zusammensetzungen Using organo siloxane block copolymers for the preparation of cosmetic or pharmaceutical compositions
11/26/2009	CA2826508A1 Nanoemulsion vaccines
11/26/2009	CA2762321A1 Fosphenytoin composition
11/26/2009	CA2761971A1 Rice bran extracts for inflammation and methods of use thereof
11/26/2009	CA2725535A1 Modified drugs for use in liposomal nanoparticles
11/26/2009	CA2725529A1 Liposomes for drug delivery and methods for preparation thereof
11/26/2009	CA2725513A1 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
11/26/2009	CA2725329A1 Nanoemulsion vaccines
11/26/2009	CA2724594A1 Niacin and nsaid combination therapy
11/26/2009	CA2709808A1 Treatment of dysmenorrhea via transdermal administration of nonsteroidal anti-inflammatory drugs
11/25/2009	EP2123296A1 Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing the same
11/25/2009	EP2123295A1 Therapeutic agent for interstitial pneumonia
11/25/2009	EP2123288A1 C<sb>70</sb>-containing liposome, method for producing the same, and use of the same
11/25/2009	EP2123286A1 A nanoparticle of glucidamin for treating tumor and preparation method thereof
11/25/2009	EP2123284A1 Prophylactic and/or therapeutic agent for cardiac infarction
11/25/2009	EP2123283A1 The tetracyclic anthraquinones possessing anti-cancer effect
11/25/2009	EP2123278A1 Eye drop reparation comprising latanoprost
11/25/2009	EP2123275A1 Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa
11/25/2009	EP2123274A1 Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same
11/25/2009	EP2123270A1 Iron metabolism-improving agent
11/25/2009	EP2123262A1 Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier
11/25/2009	EP2123261A1 Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
11/25/2009	EP2123260A1 Liposome formulation and process for preparation thereof
11/25/2009	EP2123259A1 Liposome preparation for iontophoresis having antioxidant component encapsulated therein
11/25/2009	EP2123258A1 Liposomes for drug delivery
11/25/2009	EP2123257A2 Stable high Vitamin C content polyol-in-oil emulsified system and its preparation
11/25/2009	EP2123256A1 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
11/25/2009	EP2123255A1 Pharmaceutical composition containing fine particle oil-based suspension
11/25/2009	EP2121716A1 Compositions of stable tiacumicins
11/25/2009	EP2121479A2 Complementary personal lubricant compositions and delivery system
11/25/2009	EP2121139A1 Formulations for cancer treatment
11/25/2009	EP2121088A2 Heating unit for use in a drug delivery device
11/25/2009	EP2121057A1 Polymerization with precipitation of proteins for elution in physiological solution
11/25/2009	EP2121027A2 Cyclodextrin formulations
11/25/2009	EP2121025A2 Methods and compositions for the delivery of a therapeutic agent
11/25/2009	EP2121023A1 Controlled release composition and process
11/25/2009	EP2120990A1 Reducing post-operative adhesion formation with intraperitoneal glutamine
11/25/2009	EP2120955A1 Pellets comprising an active substance matrix and a polymer coating, and a method for producing said pellets
11/25/2009	EP2120946A1 Pharmaceutical composition comprising nicotinamide or nicotinic acid
11/25/2009	EP2120914A1 Use of gentian violet in treatment of atopic dermatitis
11/25/2009	EP2120913A2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
11/25/2009	EP2120908A1 Solvating system and sealant for medical use
11/25/2009	EP2120897A2 Polymer-based films and drug delivery systems made therefrom
11/25/2009	EP2120896A1 Medically active plaster
11/25/2009	EP2120895A2 High dose film compositions and methods of preparation
11/25/2009	EP2120894A1 Oral submicron particle delivery system for proteins and process for its production
11/25/2009	EP2120893A1 Protein-containing substance with increased thermal stability
11/25/2009	EP2120892A1 A lactase formulation
11/25/2009	EP2120891A2 Polynuclear microcapsules
11/25/2009	EP2120890A2 Coated pellets
11/25/2009	EP2120889A1 Gelatin capsules comprising an acid
11/25/2009	EP2120888A1 Time- specific delayed/pulsatile release dosage forms
11/25/2009	EP2120887A1 Controlled-release preparation containing cilostazol and process for the preparation thereof
11/25/2009	EP2120886A2 Modified-release formulations of azabicyclo derivatives
11/25/2009	EP2120885A2 Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile
11/25/2009	EP2120884A1 Pharmaceutical composition
11/25/2009	EP2120883A1 Pharmaceutical composition comprising a salt of rosiglitazone
11/25/2009	EP2120882A2 Pharmaceutical composition containing a cholesterol absorption inhibitor
11/25/2009	EP2120881A2 Method of determining the weight of the coating to be applied to form a controlled release dosage form
11/25/2009	EP2120880A2 Pellets comprising an active substance matrix resistant to gastric juice
11/25/2009	EP2120879A2 Disintegration promoters in solid dose wet granulation formulations
11/25/2009	EP2120878A1 A dosage form containing two or more active pharmaceutical ingredients in different physical forms
11/25/2009	EP2120877A2 Imatinib mesylate
11/25/2009	EP2120876A2 Nanoparticle delivery systems for membrane-integrating peptides
11/25/2009	EP2120875A1 Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
11/25/2009	EP2120874A2 Oral contraceptive spray
11/25/2009	EP2120873A1 Topical dosage form comprising tri-substituted glycerol compounds
11/25/2009	EP2120872A1 Nanoemulsion

1 ... 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 ... 2991